Toxic hepatitis after sequential administration of flutamide and cyproterone acetate

Digestive Diseases and Sciences

Volumn 49, Issue 3, 2004, Pages 462-465

  Manolakopoulos, Spilios ^a,c   Bethanis, Sotirios ^a   Armonis, Anastasios ^a   Economou, Michalis ^a   Avgerinos, Alec ^b   Tzourmakliotis, Dimitrios ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Cyproterone acetate; Drug induced liver disease; Flutamide; Ursodeoxycholic acid

Indexed keywords

BILIRUBIN; CYPROTERONE ACETATE; ELITYRAN; FLUTAMIDE; LEUPRORELIN; URSODEOXYCHOLIC ACID;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; DRUG INDUCED DISEASE; ECHOGRAPHY; HUMAN; JAUNDICE; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SEQUENTIAL DRUG ADMINISTRATION; TOXIC HEPATITIS;

AGED; ANDROGEN ANTAGONISTS; BILIRUBIN; CYPROTERONE ACETATE; FLUTAMIDE; HEPATITIS, TOXIC; HUMANS; LIVER FUNCTION TESTS; MALE;

EID: 1842451743     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000020504.41500.9c     Document Type: Article

References (25)

1. Ridell JG, Harron DW, Shanks RG: Clinical pharmacokinetics of beta-adrenoreceptor antagonists. An update. Clin Pharmacokinet 12(5):305-320, 1987
2. Borchard U: Pharmacokinetics of beta-adrenoreceptor blocking agents: Clinical significance of hepatic and/or renal clearance. Clin Phys Biochem 8 (Suppl)2:28-34, 1990
3. Crawford ED, Eisenberger MA, McLeod DG, et al.: A conrolled trial of leuprorelide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989
4. Friedman A, Narcross MJ, Rein M: Adverse effects of leuprorelide acetate depot treatment. Fertil Steril 59:448-450, 1993
5. Migliari R, Muscas G, Murru M, et al.: Antiandrogens: A summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Arch Ital Urol Androl 71(5):293-302, 1999
6. Gomez JL, Dupont A, Cusan L, et al.: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Isr J Med 92:465-470, 1992
7. Wysowski D, Freiman JP, Tourtelot JP, et al.: Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118:860-864, 1992
8. Garcia Cortes M, Andrade RJ, Lucena MI, et al.: Flutamide-induced hepatotoxicity: report of a case series. Rev Esp Enferm Dig 93(7):419-422, 2001
9. Dourakis S, Alexopoulou A, Hadziyannis S: Fulminant hepatitis after flutamide treatment. J Hepatol 20:350-353, 1994
10. Cetin M, Demirci D, Unal A, et al.: Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 18(3):137-140, 1999
11. Hinkel A, Berges RR, Pannek J, et al.: Cyproterone acetate in the treatment of advanced prostatic cancer: retrospective analysis of liver toxicity in the long-term follow up of 89 patients. Eur Urol 30(4):464-470, 1996
12. Levesque H, Trivalle C, Manchon ND, et al.: Fulminant hepatitis due to cyproterone acetate. Lancet 1:215-216, 1989
13. Parys BT, Hamid S, Thomson RGN: Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J Urol 67:312-313, 1991
14. Hirsch D, Kovatz S, Bemheim J, et al.: Fatal fulminant hepatitis from cyproterone acetate. Isr J Med Sci 30:238-242, 1994
15. Bressolette L, Dubois A, Carlhant D, et al.: Fatal hepatitis caused by cyproterone acetate. Therapie 49(2):153, 1994
16. Friedman G, Lamoureux E, Sherker A: Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci 44(7): 1362-1363, 1999
17. Scheuer PJ: Liver biopsy interpetation, 4th ed. Philadelphia, Bailliere Tindall, 1988, pp 99-112
18. Trauner M, Graziadei IW: Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 13(8):979-996, 1999
19. Kallinowski B, Theilmann L, Zimmermann R, et al.: Effective treatment of cyclosporine-induced cholestasis in heart-transplanted patients treated with ursodeoxycholic acid. Transplantation 51:1128-1129, 1991
20. Cicognani C, Malavolti M, Morselli-Labate A, et al.: Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis. Dig Dis Sci 41(11):2219-2221, 1996
21. Soza A, Riquelme F, Alvarez M, et al.: Hepatotoxicily by amoxycillin/clavulanic acid: case report. Rev Esp Enferm Dig 90(7):523-526, 1998
22. Barrio J, Castiella A, Lobo C, et al.: Cholestatic acute hepatitis induced by amoxycillin-clavulanic acid combination. Role of ursodeoxycholic acid in drug-induced cholestasis. Rev Esp Enferm Dig 90(7):523-526, 1998
23. Katsinelos P, Vasiliadis T, Xiarchos P, et al.: Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: Report of two cases. Eur J Gastroenterol Hepatol 12(3):365-368, 2000
24. Habscheid W, Abele U, Dahm HH: Severe cholestasis with kidney failure from anabolic steroids in a body builder. Dtsch Med Wochenschr 124(36):1029-1032, 1999
25. Salmon L, Montet JC, Oddoze C, et al.: Ursodeoxycholic acid and prevention of tacrine-induced hepatotoxicity: a pilot study. Therapie 56(1):29-34, 2001